PwC Medical Technology Innovation Scorecard. Update June 2010

Transcription

1 PwC Medical Innovation Scorecard Update June 2010

2 Innovation scorecard goal Slide 2

3 Innovation scorecard timeline of events Spring 2009 Innovation Scorecard announced in Rome Spring 2009 Fall / Winter 2009 Concept Development & Survey Deployment May 2010 Innovation Scorecard Update Summer 2010 Complete Scorecard and Survey Analysis Fall 2010 Fall 2010 Innovation Scorecard Launch Slide 3

4 Innovation scorecard framework Innovation Scorecard Regulatory Environment Access Demographics Market Factors Policy & Compliance Access to Care Demographics of Disease Fiscal Environment Payment & Reimbursement Access to Demographics of Innovative Talent Medical Market Success Slide 4

5 Markets studied United Kingdom Germany United States France Israel China Japan Brazil India Slide 5

6 Innovation scorecard - Impact Regulatory Environment Which regulatory and reimbursement environments are the most attractive for the introduction of innovative medical technologies? Access Which countries are better equipped with the healthcare and technological infrastructure to deliver innovative medical technologies? Demographics In which markets is the capacity for innovation and the advancement of medical technology the greatest? Market Factors Which countries have the most attractive market opportunity for innovative medical technologies? Slide 6

7 Innovation scorecard Sample of metrics Regulatory approval (time) Regulatory approval (costs) Period of device product registration Ease of doing business Intellectual property protection Policy & Compliance Ease of regulatory approval Corruption Perceptions Index score Government transparency Laws relating to information technology Prevalence of trade barriers Venture capital investment Royalty and license fee receipts Private foreign direct investment GDP growth Fiscal Environment Expenditures on Research and Development New business density Extent and effect on taxation Medical Success Factors Medical device market per capita Medical device exports Number of medical device companies Medical device market access Attractiveness of commercial opportunity Ease of medical device availability and willingness to pay Compounded annual growth rate of sales Compounded annual growth rate of units Slide 7

8 Consolidated results Slide 8

9 Historical trends analysis - Example CAGR of Clinical Trials by Country CAGR of Global Clinical Trials: 56.7% % 140% 120% 100% 80% 60% 40% 20% 0% 48% 117% 59% 60% 56% Brazil China France Germany India Izsrael Japan United Kingdom Clinical Trials by country as percentage of total clinical trials 2004 & % 123% 53% 40% United States Brazil China France Germany India Israel Japan UK US % 0.5% 5.5% 6.0% 1.4% 1.5% 0.3% 5.6% 78.7% % 2.5% 6.0% 6.6% 1.4% 2.6% 1.9% 5.0% 45.0% Change Source: clinicaltrials.gov Note: Date of clinical trial is the date when the clinical trial was first submitted to ClinicalTrials.gov Slide 9

10 Innovation scorecard by dimension Illustrative United States United Kingdom Japan Israel 5.0 India Germany 4.0 France China 3.0 Brazil Overall Score Regulatory Payment & Reimbursement Access to Care Access to Demographics of Demographics of Disease Innovative Talent Fiscal Environment Medical Market Success Slide 10

11 Innovation scorecard by market China United States Medical Market Success Fiscal Environment Regulatory Payment & Reimbursement Access to Care Medical Market Success Fiscal Environment Regulatory Payment & Reimbursement Access to Care Demographics of Innovative Talent Demographics of Disease Access to Demographics of Innovative Talent Demographics of Disease Access to Illustrative Illustrative Slide 11

12 Innovation scorecard with future scenarios Illustrative United States China Slide 12

13 2010 LLP. All rights reserved. "" refers to LLP, a Delaware limited liability partnership, or, as the context requires, the global network or other member firms of the network, each of which is a separate and independent legal entity. This document is for general information purposes only, and should not be used as a substitute for consultation with professional advisors.